[A18-72] Abemaciclib in combination with an aromatase inhibitor (breast cancer) - Benefit assessment according to §35a Social Code Book V
Last updated 02.05.2019
Project no.:
A18-72
Commission:
Commission awarded on 29.10.2018 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Women with HR-positive, HER2-negative locally advanced or metastatic breast cancer
Initial endocrine therapy in postmenopausal women: indication of lesser benefit in comparison with appropriate comparator therapy. Subsequent endocrine therapy and/or pre- or perimenopausal women: added benefit not proven due to a lack of study data.
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A20-32 | Abemaciclib (breast cancer; combination with fulvestrant) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A19-24 | Abemaciclib (breast cancer; combination with an aromatase inhibitor) - Addendum to Commission A18-72 | Commission completed |
| A18-73 | Abemaciclib in combination with fulvestrant (breast cancer) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A22-137 | Abemaciclib (breast cancer; combination with an aromatase inhibitor) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| A22-51 | Abemaciclib (breast cancer) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| A21-153 | Abemaciclib (breast cancer; combination with fulvestrant) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2019-05-02 A G-BA decision was published.